Esac, 155 Gibbs St, Unit 420, Rockville, MD 20850, US

ReveraGen BioPharma, Inc. is a leading biopharmaceutical company based in Rockville, MD, specializing in the development of innovative therapies for Duchenne muscular dystrophy (DMD) and other related indications. Their flagship product, AGAMREE vamorolone, has received approval from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), making it the first therapy for DMD to achieve dual regulatory clearance. With a focus on venture philanthropy, ReveraGen BioPharma is dedicated to advancing drug development through cutting-edge research, clinical trials, and strategic partnerships. Driven by a commitment to improving the lives of individuals affected by DMD, ReveraGen BioPharma has demonstrated the efficacy and safety advantages of vamorolone over traditional treatments like prednisone. Their groundbreaking research, including studies in cells and mice, has paved the way for clinical testing in DMD and Becker muscular dystrophy. By leveraging innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models, ReveraGen BioPharma is at the forefront of revolutionizing the treatment landscape for muscular dystrophy and bringing hope to patients worldwide.Generated from the website

Equivio

Smss Foundation

Synthetic Biologics

Clean Currents Solar of the Mid Atlantic